Group items tagged

The British scientists behind one of the major therapeutic Covid-19 trials have turned their focus to treatments for monkeypox, a viral disease that has been labelled a global health emergency by the World Health Organization. The team from Oxford University behind the so-called RECOVERY trial - which honed in on four effective Covid treatments - on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether Siga Technologies' tecovirimat is an effective treatment for monkeypox. Although there are vaccines developed for the closely related smallpox that can reduce the risk of catching monkeypox, there are currently no treatments that have been proven to help hasten recovery in those who develop the disease. The UK has over 3,000 confirmed cases of monkeypox. The virus is transmitted chiefly through close contact with an infected person. It typically causes mild symptoms including fever, rash, swollen lymph nodes and pus-filled skin lesions. Severe cases can occur, though people tend to recover within two to four weeks. Siga's drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.

Pharmacists, along with workers from other public sector workplaces, marched on 8 September demanding that the Scottish government take all available action to mitigate the biggest reduction in living standards workers will have experienced for generations. Pharmacists Defence' Association (PDA) members participated in the Scottish Trade Unions Congress (STUC) march to let the government know that "Scotland demands better". Paul Flynn, PDA national officer, said: "Pharmacists will be unwelcomely familiar with diminished purchasing power and a squeeze on household budgets for patients, colleagues and pharmacists but what we will see this year and into 2023 will make previous experience pale by comparison." The march organised by STUC saw thousands of workers, activists and concerned individuals march through the centre of Edinburgh's Historic Old Town in good spirits while bearing flags and banners, chanting, singing, and calling for change in Scotland.

The Pharmacists' Defence Association (PDA) has reacted to the chief pharmaceutical officer (CPhO) for Wales's offer for community pharmacy contractors, offering a funding uplift for community pharmacy on the condition of an increase in pay for some staff by at least the amount currently being imposed upon NHS employees. The PDA has expressed a mixed reaction to the intervention being attempted by the Welsh government. "It is unusual for a government to be so closely involved in the pay of their suppliers' employees and those at some community pharmacy employers have a contractual right to a pay review at times of year that may not synchronize with the government's financial cycle, so this initiative may have different impacts at different employers," said the association. "In addition, the PDA negotiates pay at the largest two community pharmacy employers and works alongside other trade unions that organise other pharmacy workers. This government intervention must not disrupt or attempt to bypass those processes."

The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal remain disputed. RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay deal, and requested an urgent meeting to discuss their dispute. Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued. "The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who received the lowest pay rise in the public sector," she wrote in the letter. NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.

The European Commission is prepared to rewrite European Union law on medicines to ensure stable supply of generic and life-saving medicines in Northern Ireland. In a press statement issued on Friday (Dec 17), the commission said it put forward a package of measures to ensure the continued long-term supply of medicines from Great Britain to Northern Ireland. In the context of the Northern Ireland Protocol, this means that the same medicines will continue to be available at the same time across the United Kingdom. Commenting on the news, policy manager at the National Pharmacy Association (NPA) Helga Mangion said: "We are encouraged by the EU's statement on medicines availability in Northern Ireland, though of course we await the final outcome of the negotiations. We have been talking to the government, the MHRA and other stakeholders about these issues for months, highlighting the concerns of our members in Northern Ireland."

All children aged five to 11 in England will be offered a Covid-19 vaccine, the government said on Wednesday (February 16) - following similar announcements in the rest of the UK. The move, coming nearly two months after British regulators approved Pfizer and BioNTech's shot for use among the age group, sees Britain following the lead of the United States, the European Union and other countries. It has only been vaccinating at-risk under-12s and those who live with immuno-suppressed people, using a lower-dose formulation of the jab that was found to be "safe and effective". However, health secretary Sajid Javid - who has responsibility for England only - said he had now accepted guidance from the Joint Committee on Vaccination and Immunisation, which advises UK health departments, to expand the rollout. "The NHS will prepare to extend this non-urgent offer to all children during April so parents can, if they want, take up the offer to increase protection against potential future waves of Covid-19 as we learn to live with this virus," he said in a statement.

While responding to the consultation on hub and spoke dispensing, trade unions for pharmacists have emphasised that the patient safety and care must be the priority in hub and spoke dispensing. The Royal Pharmaceutical Society (RPS) has welcomed the opportunity provided by a change in legislation to enable community pharmacies to make use of hub and spoke dispensing but reaffirmed that patient care must be at the heart of future changes. With regards to patient safety, the Pharmaceutical Services Negotiating Committee (PSNC) considers that only Model 1 is appropriate, with manageable risks related to patient safety, and is a model that has the potential to allow the whole sector to benefit fairly. In its response to the consultation on Hub and Spoke dispensing, PSNC highlighted that Model 2 in the consultation, a hub direct to patient supply of dispensed medicines, raises patient safety issues and it cannot be supported. RPS President Professor Claire Anderson said: "In all models, patients need to continue to have access to a pharmacist at the time of supply of medicines so they have the opportunity to discuss, ask questions or raise concerns, and receive appropriate information with counselling and advice.

The Pharmacists' Defence Association (PDA) has called for a mandatory training for those who wish to sign fit notes. The union said it will be seeking urgent clarification around the rollout of guidance and timescales of when this will be available to PDA members working in primary care and hospitals, who will be at the forefront of the implementation. "As with any activity, regulated health professionals will be expected to ensure they have received adequate training and guidance before taking on new elements of practice and to ensure they are acting within the limits of their professional competency," said the association. It also highlighted that completing a fit note may have an impact on the income received by the patient and therefore the consequences of supplying the document could mean a direct financial consequence for them, such as eligibility for sick pay or insurance claims, as well as a health outcome. The PDA expects the mandatory training to cover any factors which will need to be considered in this regard so that pharmacists understand any limitations on when, how, and for who they might complete the fit notes.

Pharmacists delivering to the Scottish prison service have been notified by their employer LloydsPharmacy that they may be transferred to another employer or even be at risk of redundancy. The Pharmacists Defence Association said: "It is supporting pharmacists employed by LloydsPharmacy who have been advised that the company has not retendered for the contract to provide pharmacy services to the Scottish prison service. As a result of LloydsPharmacy exiting the contract, those pharmacists may transfer to whichever employer takes over the service, or if their function does not transfer to a new employer they will be at risk of redundancy." The PDA Union will be representing these individuals to ensure they understand and can exercise their rights at work to either continue their current role under a new employer, transfer to a suitable alternative role, or leave with the appropriate redundancy compensation. PDA members impacted by this change can contact the PDA Service Centre for advice.

The Pharmacists' Defence Association raised concerns over the practice of firing and rehiring employees, which often leads to denial of individuals' rights to redundancy, forcing them to face cuts to their terms and conditions. It noted that some employers may use the 'fire and rehire' practice to force staff to accept lower wages, different hours, or other changes in working conditions. It cited an example of a lawsuit in which Tesco lost a High Court battle when Usdaw won a case to protect workers from unfair tactics. The PDA said although the trade union won the case, the practice of firing and rehiring can still be legal in some circumstances. However, it believes the practice is both immoral and unethical.

The European Union's health regulator on Friday said it had recommended granting a conditional marketing authorisation for a gene therapy by Australian drugmaker CSL Ltd and partner uniQure N.V. , to treat haemophilia B, a rare bleeding disorder which is caused by genetic anomalies. About one in 40,000 people are affected by the inherited disorder, caused by a gene mutation that hampers the body's ability to make clotting protein factor IX. If approved, the treatment, branded Hemgenix, will be the first gene therapy in the European Union for the condition that is usually treated by regular injections of factor IX, the European Medicines Agency said. CSL had acquired exclusive global rights to Hemgenix in May last year from uniQure N.V.

The Medicines and Healthcare products Regulatory Agency (MHRA) made its new International Recognition procedure (IRP) fully operational from 1 January 2024, inviting developers of new medicines to submit their applications for marketing authorisation. Beginning this year, the EC Decision Reliance Procedure (ECDRP) has been replaced by IRP, and the Mutual Recognition/Decentralised Reliance Procedure (MRDCRP) has come under its umbrella. The move is expected to further improve access to life-saving medicines for UK patients following the UK's departure from the European Union.

The Pharmacists' Defence Association (PDA) is bolstering its leadership team with the appointment of Jay Badenhorst as the Director of Pharmacy, a newly created position aimed at fortifying its commitment to advancing pharmacy practice. This move comes amidst a period of significant change and challenge for frontline pharmacists, prompting the independent trade union to enhance its influence in the evolving healthcare landscape. Mr. Badenhorst, who previously served Whitworth Chemists as the Managing Director and also has leveraged his extensive knowledge of the pharmacy practice and organisational leadership as the Vice Chair of the National Pharmacy Association, reasons his "commitment to being at the forefront of positive change within the pharmacy profession." Mr. Badenhorst expressed his enthusiasm stating: "I am delighted to be joining an organisation that has so much vision, ambition and drive at a time when pharmacists have so many opportunities to develop their roles for the benefit of patients." According to Mark Koziol, Chair of PDA, the new position is a reflection of the union's commitment to pharmacy and described the new Director of Pharmacy as "a senior level, proven and award-winning pharmacy leader."

Adding to the growing evidence of global medicine shortages, a new study has revealed that the European generic medicines market is "not in shape" to help Europe meet its public health priorities. In the past decade, the rate of generic medicines withdrawals has risen by 12 per cent, while there has been a three per cent decrease in the launch of generic products, as per Teva Pharmaceuticals' recent analysis of IQVIA data. Within the mental therapeutic area, seven per cent of generic products disappeared between 2013 and 2023, while there was a seven per cent decrease in the availability of generic cancer medicines in just six years (2017-2022). These medicines were listed on the Union List of Critical Medicines to help avoid potential shortages, as the European Commission (EC) said this could cause "significant harm to patients and pose important challenges to health systems." While mature generic products constitute the majority of the List, they remain susceptible to withdrawals, despite containing products crucial for safeguarding Europe's public health, the Teva analysis report noted. Since 2013, the number of generic products for the treatment of schizophrenia and bipolar disorder has declined by 25 per cent, with Hungary and Bulgaria experiencing the biggest loss at 83 per cent and 58 per cent respectively.

Most people in Great Britain believe that new junior doctors, nurses and health care assistants are underpaid, senior doctors and matrons are paid about right, and NHS CEOs are paid too much, according to a new study. About half the people surveyed indicated that newly qualified junior doctors are paid too little, with this sentiment increasing to three in five (60 per cent) among Labour voters. The research conducted by the Policy Institute at King's College London, King's Business School, and Ipsos also showed that more people believe NHS staff overall were badly paid than well paid. Dr Nick Krachler, senior lecturer in Human Resource Management at King's Business School, said: "Our survey shows considerable alignment between public perception of NHS pay levels and the claims of trade unions and professional associations that pay levels - which are determined by government after consultation from a Pay Review Body - ​are unsatisfactory for frontline NHS roles." He highlighted the urgent need to address healthcare workers' economic wellbeing, hoping that the new government will consider it in its upcoming negotiations with junior doctors this week.

Powerlessness on the bed is the biggest insult for any man. It is sure to decline the respect, love and belongingness in the union, thus there are large numbers of separations that are taking place within couples in all parts of the globe.

Grab a chance to connect with local Businesses and exciting events happening in Macclenny, FL on Save Local Now. Check out our top listings for best offers, health & fitness, activities, financial products and services, logistics services, beauty & cosmetic products, shopping and lot more in your area. Exchange your thoughts for top businesses offering on variety of services and share them with your friends and social networks.

The Pharmacists' Defence Association (PDA) has raised concerns over "a prominent pharmacist's call to create a sector 'blacklist' for locums regarding disputes over rates." A few contractors took it to the Twitter to share screenshots of the messages by locums demanding more pay, which led to the call for 'blacklisting' those locums. "The motivation regarding the current talk of creating a blacklist seems intrinsically tied to hourly rates. Although there are occasional and isolated anecdotal reports on social media of alleged incidents of locums seeking higher rates than already agreed, these are far outstripped by reports of pharmacy businesses unwilling to negotiate and who do not want to pay the necessary rate to engage a locum and instead have set capped or fixed rates," said the PDA. It added that all parties should honour agreements they enter into, including a pharmacy's commitment to the NHS that it will open at set times to provide pharmaceutical services to patients and the public.

After a series of internal pay negotiations and conciliation meetings, Boots has made a revised pay offer to its pharmacists. With the new development, the Pharmacists' Defence Association (PDA) has urged its members at Boots to "urgently respond to the Boots pay negotiations update survey on the current pay offer." It encouraged the members to complete the short survey sent to them via email. Last week, the PDA Reps Network in Boots hosted a series of virtual meetings for members that work at the company. As the element of the negotiations with Advisory, Conciliation and Arbitration Service (ACAS) are ongoing, PDA could not provide more details about these meetings.

The public awareness campaign for community pharmacy, 'Ask Your Pharmacist Week' this year will be on 31 October - 7 November, the National Pharmacy Association (NPA) has announced. Every year AYP Week is held across the UK, with an aim to raise awareness of pharmacy services and to prompt conversations with key stakeholders at a local level about community pharmacy's role and benefits. Activities in previous years have ranged from public exhibitions and window posters to social media campaigns, projects with patient groups and visits to pharmacies from local dignitaries and politicians. NPA Head of Communications, Stephen Fishwick, said, "AYP Week is an important fixture in the pharmacy calendar, as it creates a space for focused public awareness activities to help customers, patients and stakeholders understand more fully the community pharmacy offer. We want people to be more aware of long-standing and new NHS services plus the skills and expertise on offer in pharmacies across the UK. AYP also aims to cultivate a richer dialogue with key stakeholders, which in England now includes leaders in Integrated Care Systems."